Chapter 10 Heart Disorders
Box 10-1 Cardiac Physical Diagnosis
10-3: Distention of internal jugular vein: The patient has right-sided heart failure.
(From http://courses.cvcc.vccs.edu/WisemanDljugular_vein_distention.htm)
Nonpharmacologic therapy in congestive heart failure involves restricting sodium (<2 g/day) and water (<2 L/day), both of which are increased due to the decreased cardiac output and renal retention of sodium and water (refer to Chapter 4). Systolic dysfunction is treated with drugs that reduce the workload of the left ventricle. This is accomplished by decreasing afterload and preload. A mainstay of treatment for systolic dysfunction are the angiotensin-converting enzyme (ACE) inhibitors or receptor inhibitors if patients develop chronic cough. ACE inhibitors decrease afterload by decreasing angiotensin II and decrease preload by decreasing aldosterone. Diuretics (e.g., loop diuretics, aldosterone blockers) complement ACE inhibitors by decreasing preload. β-Blockers decrease sympathetic tone, which reduces myocardial O2 consumption. Digitalis may be useful because of its inotropic and vagotonic effects particularly in severe heart failure or those with atrial arrhythmias. Direct vasodilating drugs (e.g., hydralazine) reduce systemic vascular resistance and pulmonary venous pressure. Therapeutic options for treating diastolic dysfunction are based on the cause of diastolic dysfunction. If hypertension is the primary cause, calcium channel blockers, ACE inhibitors, and β-blockers are used, the latter decreasing heart rate, which prolongs diastolic filling. Diuretics must be used with caution, because excessive diuresis may produce volume depletion and decrease the cardiac output.
Nonpharmacologic therapy of angina includes losing weight, cessation of smoking, placing the patient on a low cholesterol diet, and encouraging daily aerobic exercise. Pharmacologic therapy for angina involves the use of anti-ischemic agents. Nitrates (release nitric oxide) cause venodilation (reduces preload and wall tension in the ventricles), vasodilation of the coronary arteries, and vasodilation of peripheral resistance arterioles (reduces afterload). β-Blockers decrease myocardial O2 consumption by reducing heart rate and systolic blood pressure. Calcium channel blockers cause vasodilation of the coronary arteries and peripheral resistance arteries. They are the drug of choice for treating Prinzmetal’s angina. Aspirin inhibits platelet aggregation, which decreases the risk for developing a platelet thrombus (refer to Chapters 4 and 14). Heparin plus aspirin is used for patients with unstable angina and reduces the risk for developing a myocardial infarction and refractory angina. If homocysteine levels are increased, the patient should be placed on pharmacologic doses of folate. If C-reactive protein is increased, the patient should be placed on “statin” drugs to lower the LDL levels to 70 mg/dL or less. This stabilizes disrupted plaques and reduces the risk for thrombosis. Revascularization procedures include percutaneous transluminal coronary angioplasty (PTCA) and stenting. Balloon angioplasty dilates and ruptures the atheromatous plaque to improve blood flow (restenosis commonly occurs) and intracoronary stents (the most common procedure) bypass the obstruction (restenosis less common). Complications are associated with either procedure (e.g., thrombosis, localized dissection). In order to prevent platelet thrombosis in these revascularization procedures, abciximab (inhibits the GpIIb-IIIa fibrinogen receptor in platelets; refer to Chapter 14) is used. Coronary artery bypass graft (CABG) is reserved for patients with left main coronary artery disease and for those patients with symptomatic three-vessel disease. Internal mammary artery grafts have the best graft patency after 10 years, while saphenous vein grafts commonly show “arterialization” of the vessels with fibrosis after 10 years.